our proprietary products products using alkermes technologies
TRANSCRIPT
Our Proprietary Products
Our commercial product portfolio reflects our years of experience in drug development and our patient-centered approach. Our medicines address patient needs in major disease areas.
ARISTADA® (aripiprazole lauroxil) extended-release is a injectable suspension long-acting atypical antipsychotic that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia.
ARISTADA is available in four dose strengths with once-monthly dosing (441 mg, 662 mg, 882 mg), a six-week dosing option (882 mg) and a two-month dosing option (1064 mg).
For important safety and full product information, please visit www.aristada.com.
VIVITROL® (naltrexone for extended-release injectable suspension) is a once-monthly, non-narcotic, injectable medication approved in the U.S., Russia and certain countries of the CIS for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.
For important safety and full product information, please visit www.vivitrol.com.
WEBSITEwww.alkermes.com
TICKER SYMBOLNasdaq: ALKS
EMPLOYEESApproximately 2,000 WW
CONTACTSMedia Relations Voice: +1 781 609 [email protected]
Investor RelationsVoice: +1 781 609 [email protected]
Blair JacksonSenior Vice President, Business DevelopmentVoice: +1 781 609 6594
About Us
At Alkermes plc, our employees consistently strive to provide physicians and patients with treatment options that address important unmet needs. Through our scientific expertise, proprietary technologies and global resources, we are uniquely positioned to continue building a portfolio of medicines for major clinical conditions with a focus on central nervous system (CNS) disorders.
Our success to date is evident from our diverse commercial product portfolio, including treatments in major diseases, such as schizophrenia and addiction. Beyond our commercial products, we have a promising pipeline of proprietary drug candidates, many in late-stage development. Both our commercialized products and rich pipeline demonstrate our leadership in drug development for CNS diseases, a therapeutic area where we have established expertise and a promise for delivering new treatments.
A Perspective From our CEO, Richard Pops
“This is an amazing company because we’re actually going
after some of the most important diseases that affect
mankind… where the burden of disease is still massive around
the world…”
Richard F. PopsChairman and Chief Executive Officer
Alkermes plc is a fully integrated, global
biopharmaceutical company developing
innovative medicines for the treatment of central
nervous system (CNS) diseases. The company has
a diversified commercial product portfolio and a
substantial clinical pipeline of product candidates for
chronic diseases that include schizophrenia,
depression, addiction and multiple sclerosis.
Rev: February 2018
CLINICAL DEVELOPMENT PROGRAMS
Preclinical Phase 1 Phase 2 Phase 3FDA
SubmissionCANDIDATE
ALKS 5461 (Major Depressive Disorder)
Aripiprazole Lauroxil NanoCrystal® Dispersion (Intiation product for ARISTADA®)
ALKS 3831 (Schizophrenia)
BIIB098 (fomerly ALKS 8700) (Multiple Sclerosis)
ALKS 4230 (Immuno-oncology)
At Alkermes plc, we approach the development of new therapeutics with a thoughtful focus on patients’ real-world needs. We are committed to providing patients and caregivers with medicines that offer benefits in terms of safety, efficacy and ultimately health outcomes. This is illustrated by our focused and advancing pipeline.
TOP PLACES TO WORK - 2017
LEARN MORE ABOUT US
@Alkermes
linkedin.com/company/alkermes/
GLOBAL PRESENCE
Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
Athlone, Ireland Facility
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000
Waltham, Massachusetts Facility
852 Winter Street
Waltham, MA 02451
+1 781 609 6000
Wilmington, Ohio Facility
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642
OUR CORPORATE INFORATION
OUR PURPOSE
Great Science Deep CompassionReal Impact